



AMERICAN  
COLLEGE of  
CARDIOLOGY

---

Heart House

2400 N Street, NW  
Washington, DC 20037-1153  
USA

202.375.6000  
800.253.4636  
Fax: 202.375.7000  
[www.ACC.org](http://www.ACC.org)

---

*President*

Richard A. Chazal, MD, FACC

*President-Elect*

Mary Norine Walsh, MD, FACC

*Vice President*

C. Michael Valentine, MD, FACC

*Treasurer*

Robert A. Guyton, MD, FACC

*Secretary and Board of Governors Chair*

A. Allen Seals, MD, FACC

*Trustees*

Deepak L. Bhatt, MD, MPH, FACC  
Paul N. Casale, MD, MPH, FACC  
Richard A. Chazal, MD, FACC  
Robert A. Guyton, MD, FACC  
Robert C. Hendel, MD, FACC  
Dipti Itchhaporia, MD, FACC  
Christopher M. Kramer, MD, FACC  
Michael J. Mack, MD, FACC  
Frederick A. Masoudi, MD, MSPH, FACC  
Jagat Narula, DM, MD, PhD, MACC  
Debra L. Ness, MS  
Jane W. Newburger, MD, MPH, FACC  
Patrick T. O'Gara, MD, MACC  
A. Allen Seals, MD, FACC  
C. Michael Valentine, MD, FACC  
Thad F. Waites, MD, FACC  
Mary Norine Walsh, MD, FACC  
Kim Allan Williams Sr., MD, MACC  
B. Hadley Wilson, MD, FACC

*Chief Executive Officer*

Shal Jacobovitz

---

*The mission of the American College  
of Cardiology and the American  
College of Cardiology Foundation  
is to transform cardiovascular care  
and improve heart health.*

September 2, 2016

Dear LDL: Address the Risk Think Tank participants,

Thank you for accepting the invitation to participate in this Think Tank. As an esteemed participant, you are joining representatives from several medical specialty societies, industry, health systems, and other stakeholder groups to discuss challenges in lipid management. Your engagement in this initiative will help the American College of Cardiology (ACC) as we make strides toward improving patient outcomes.

The purpose of the Think Tank is to bring together a diverse group of experts to identify and discuss the barriers around implementing evidence-based LDL-C lowering therapies for ASCVD reduction as it relates to challenges faced by clinicians, patients and their systems of care. The goal is to draw on the collective experience and wisdom of participants to identify issues and inform the development of ACC practical guidance for clinicians in areas where evidence may be limited, new and evolving, or lack sufficient data to fully inform clinical decision making.

The aim of this meeting is not to reach consensus; we aim to uncover the challenges faced and hope to explore ideas of how the ACC can better serve clinicians and patients in managing dyslipidemia. Your valuable input will help to steer our work to support the broader community caring for patients at high risk, and improve patient outcomes.

As you will see in the enclosed agenda, the day will be organized by three sessions with brief thought provoking presentations to introduce key topics. Each session will direct participants to work together in small groups to discuss several questions that are provided for you in this book, and then will share their combined thoughts with the full group.

In preparation for the Think Tank, we have assembled briefing materials for your review. Given the difference in participants' backgrounds, we have selected what we believe to be the most important materials for everyone to be familiar with at the meeting, including the agenda, discussion questions and articles of interest. We hope that you will familiarize yourself with these materials before the meeting to encourage a productive discussion. We encourage all participants to consider the discussion questions in advance of the meeting, and encourage you to discuss with your colleagues to collect additional perspectives and thoughts to bring with you to the Think Tank.

If you have any questions, please contact Ashleigh Covington at [acovington@acc.org](mailto:acovington@acc.org) or 202.375.6444.

We look forward to your participation and contribution to the LDL: Address the Risk Think Tank.

Sincerely,

Christie M. Ballantyne, MD, FACC, FACP, FNLA  
Chair of LDL: Address the Risk Think Tank